

3<sup>rd</sup> International Conference on  
**DERMATOLOGY AND COSMETOLOGY**

August 17, 2023 | Webinar

Received date: 15-04-2023 | Accepted Date: 17-04-2023 | Published Date: 25-08-2023

## Healing, recurrence and second primary tumor in patients with facial basal cell carcinoma treated with a combination of interferon alpha-2b and gamma after 5 year- follow-up

**Vladimir Sánchez Linares**

Medical Science University, Cuba

**Introduction:** Among the non-surgical treatments for basal cell carcinoma (BCC) is interferon, although the main guidelines do not recommend it. More evidences on its effectiveness and safety are needed.

**Objective:** To describe the effectiveness and safety of HeberFERON in the long term in the treatment of facial basal cell carcinoma in a context of usual medical practice in primary health care.

**Methods:** This was an observational case series design. Patients with facial BCC, not amenable to surgical treatment. Perilesional a combination of interferon alpha-2b and gamma was administered for 3 weeks. Patients were Follow-up for 5 years. The main outcomes variables were cure, recurrence, the appearance of a second tumor, and adverse effects.

**Results:** 210 patients were included. After treatment, 156 (76%) patients (95% CI 68.5% to 80.7%) were cured. Those with partial response and stable disease had their tumors removed and declared cured. All cured patients were followed up for 5 years, 19 dropped out. Survival analysis showed that they developed a recurrence at 55.9 months (95% CI 54.3 to 57.5) and a second CBC at 52.4 months (95% CI 50.2 to 54.6). Tumor size, previous treatment, age, and the presence of multiple lesions were associated with outcomes. Adverse effects were frequent but not serious and allowed the treatment to be completed. Conclusions: The combination of interferon alpha-2b and gamma is comparable to other non-surgical therapies for BCC. It may be the first-line non-surgical treatment for facial BCC and pre-surgical treatment in primary care.

### References

1. Sánchez Linares V, Brito García E, Bello Rivero I. Remote effect of interferons in basal cell carcinoma. Journal of Dermatology & Cosmetology Volume 6 Issu e 4 – 2022: 105-106. Available in:
2. Sánchez Linares V, Nápoles Valdés MB, Martínez Fando B , Rondón Madrigal E. Dermatitis herpetiforme en un adolescente. Dermatol Rev Mex. 2022; 66 (5) 552-557. Available in:
3. Sánchez Linares V, Bello Rivero I. HeberFERON y calidad de vida en el carcinoma basocelular facial. Revista Gaceta Médica Espirituana. 2022. Volumen 26 (1).
4. Sánchez Linares V, Niedo Rosales L, Martínez Fando B, Brito Garcia E, Bandomo Garcia NE. Nitrógeno líquido en el tratamiento de pacientes con alopecia areata del cuero cabelludo. Folia Dermatológica Cubana. 2022;16(1): e317.

### Biography

Vladimir Sánchez Linares this to complete your PHD to the 46 years in next September at the University Medical Sciences of Sancti Spiritus Cuba. He is the head of the skin cancer program and postgraduate professor of dermatology too, is a teacher and assistant investigator. He as 30 publications. He is reviewer for the journal Gaceta Médica Espirituana in Sancti Spiritus Cuba.

vladisanchezl76@gmail.com